Resumen
Cervical cancer ranks as the fourth most common malignant neoplasm among women worldwide. In low-income countries, the diagnosis usually occurs at advanced stages, with the recommendation of chemoradiotherapy. When this initial approach fails, with persistent disease or even in the context of tumor recurrence, pelvic exenteration (PE) becomes a therapeutic option to be considered. The criteria for recommending PE have evolved over time, influenced by advancements in surgical techniques and perioperative care. These developments have enhanced the capacity for extended resections and expanded treatment possibilities for patients who were previously limited to palliative measures. Through this review, we aim to provide insights and tools to facilitate the identification of patients who may benefit from such a complex procedure.